Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 36.26M P/E - EPS this Y - Ern Qtrly Grth -
Income -22.29M Forward P/E 6.78 EPS next Y 51.20% 50D Avg Chg -1.00%
Sales 58.65M PEG -0.04 EPS past 5Y 43.93% 200D Avg Chg -10.00%
Dividend N/A Price/Book N/A EPS next 5Y 15.00% 52W High Chg -34.00%
Recommedations - Quick Ratio 0.89 Shares Outstanding 9.47M 52W Low Chg 51.00%
Insider Own 19.68% ROA -9.64% Shares Float 95.90M Beta 1.22
Inst Own 23.83% ROE - Shares Shorted/Prior 89.70K/16K Price 0.95
Gross Margin 34.28% Profit Margin -38.01% Avg. Volume 53,479 Target Price -
Oper. Margin -10.52% Earnings Date Aug 2 Volume 24,623 Change -4.14%
About Trinity Biotech plc

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Trinity Biotech plc News
11/16/24 Trinity Biotech PLC (TRIB) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
11/15/24 Trinity Biotech Announces Q3 2024 Financial Results
11/14/24 Trinity Biotech to Announce Q3 2024 Financial Results
11/07/24 Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
10/25/24 Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
10/25/24 Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
10/09/24 Trinity Biotech PLC (TRIB) Q2 2024 Earnings Call Highlights: Strong Point-of-Care Growth Amidst ...
10/08/24 Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
10/07/24 Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology
09/26/24 Trinity Biotech Acquires Preeclampsia Prediction Firm
09/25/24 Trinity Biotech's Stock Rises After Acquisition of Metabolomics
09/24/24 Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
09/18/24 Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
09/10/24 Will Trinity Biotech Stock Gain From Its Latest Patent Process?
09/09/24 Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
09/03/24 Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
08/27/24 Sector Update: Health Care Stocks Edge Higher in Late Afternoon
08/27/24 Why Is Clinical Diagnostics Focused Trinity Biotech Stock Trading Higher On Tuesday?
08/26/24 Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
08/20/24 Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
TRIB Chatroom

User Image Blberry23 Posted - 9 minutes from now

$ZONE $CERO $ELAB $HAO biotechs are hot!! $TRIB

User Image Blberry23 Posted - 23 hours ago

@TheRealShortSqueezy $TRIB THIS WEEK

User Image deepthinker Posted - 1 day ago

$TRIB Couple points. $75 million for 2025 is overambitious. $65 million is more reasonable, but GM will go up through 2025 and SG&A will come down. Bottom line is that the underlying business with Gillard as CEO is solid and improving. It’s probably worth around $165 million or $4 a share. Of course, the problem is that cash is almost gone. It seems the plan was going to be that a CGM partner would help out here in some way. That could still happen as the 2nd trial data comes in, but Perceptive may not be able to wait much longer. So, it likely all comes down to what Perceptive chooses to do now in the absence of a partner willing to provide funding.

User Image Blberry23 Posted - 1 day ago

$TRIB bloody day in the market and bulls are still holding!!!!! We will have our day next week!

User Image 2020focus Posted - 2 days ago

$TRIB *Trinity Biotech (NASDAQ:TRIB) filed a prospectus related to the offer and resale of up to about 0.65M American Depositary shares. *This prospectus is not an offer to sell. *The company will not receive any proceeds from the sale of shares by the selling shareholder.

User Image Blberry23 Posted - 2 days ago

@ANTHONYMOMO CHECK $TRIB

User Image Blberry23 Posted - 2 days ago

$TRIB NOT MAD AT THIS! $ELAB $DRUG $CERO this is great🔥🔥🔥

User Image BrenWest Posted - 2 days ago

$TRIB Not sure how they plan to avoid the $5m payment end of January with a show of performance like that.. cash reserves at $2.8M, likely to be wiped out by the end of December. I think the simple math speaks for itself. The fabled partnership doesn’t seem to be happening so either borrow more from Perceptive, face bankruptcy, or sell the whole business. Thoughts/questions in case anyone’s interested in discussing - Very curious how John convinced three companies to give up ownership in exchange for shares in Trinity - How did they bring together this new leadership team? They poached several very seasoned professionals over the past few months - Are Sjogren’s and Premier Resolution no longer a thing? - The Redchip presentation seem to be a thing of the past. Not sure what they intended to present but I’m assuming whatever they were excited about never materialized.

User Image Brasiljunior Posted - 2 days ago

$TRIB Well, I think at this point I am just going to wait until the price dips to around $1.10 again, the load up some more! lol

User Image Blberry23 Posted - 2 days ago

$TRIB HEY $DRUG $ELAB WE CAN SQUEEZE $TRIB RIGHT NOW

User Image Blberry23 Posted - 2 days ago

$TRIB GREAT NEWS‼️‼️‼️‼️ $DRUG LETS SQUEEZE IT EVERYTHING RED

User Image Blberry23 Posted - 2 days ago

$TRIB $DRUG LETS GOOOOOOO

User Image Biospeccer Posted - 2 days ago

User Image Michaelbre Posted - 2 days ago

$TRIB on track https://www.stocktitan.net/news/TRIB/trinity-biotech-announces-q3-2024-financial-53coj4nfk6qn.html

User Image Blberry23 Posted - 2 days ago

$TRIB LFG🔥🔥🔥🔥🔥🔥 NEW $DRUG EARNINGS MEETING PR COMING

User Image deepthinker Posted - 2 days ago

$TRIB A sale of the company seems very likely given the fact that the CGM partner hasn’t committed financially to the project.

User Image Blberry23 Posted - 2 days ago

$TRIB EARININGS IN 30 MINS @Paraboljoker wya!! $DRUG

User Image BrenWest Posted - 2 days ago

$TRIB Buffalo site is closing, still no premier resolution sales, 9210 still losing market share, likely no new Trinscreen sales outside of Kenya in 2024 as John hoped, zero progress on CGM from previous update.. Cash down to $2.8m… How do they survive through the end of the year without a huge cash infusion? Can’t keep diluting us to death

User Image Clydagh Posted - 2 days ago

$TRIB we needed a pleasant surprise and got none. See you all at the next ER...sigh

User Image Blberry23 Posted - 2 days ago

@TheRealShortSqueezy check out $TRIB EARNINGS 10AM $DRUG

User Image Blberry23 Posted - 2 days ago

$TRIB EARNINGS TODAY🔥🔥 $DRUG

User Image Blberry23 Posted - 2 days ago

$TRIB ill be first😅

User Image m1ster_leboeuf Posted - 3 days ago

$TRIB Told myself not to buy more here but I couldn’t… let’s see tomorrow if it was a good idea. 😂

User Image Brasiljunior Posted - 3 days ago

$TRIB interesting article in preparation for tomorrow… https://www.benzinga.com/insights/earnings/24/11/41973043/insights-ahead-trinity-biotechs-quarterly-earnings

User Image Clydagh Posted - 3 days ago

$TRIB ER on Friday (tomorrow)

User Image Brasiljunior Posted - 3 days ago

$TRIB Q3 coming in!!!! https://www.manilatimes.net/2024/11/14/tmt-newswire/globenewswire/trinity-biotech-to-announce-q3-2024-financial-results/2004514/amp

User Image Clydagh Posted - 4 days ago

$TRIB some other news we are waiting for 1) Early Sjogrens Syndrome PLA Code (over)due Q3 2024 2) partnering agreements in relation to insulin pumps - due in next 12 months. anyone know more about this ?

User Image Brasiljunior Posted - 6 days ago

$TRIB why the price drops considering they regained full compliance??? 🤨

User Image yada010 Posted - 1 week ago

$TRIB tax loss selling til EOY

User Image deepthinker Posted - 1 week ago

$TRIB Presumably, if the CGM can’t find a partner, the company will be sold. The listing significantly enhances the sales value, particularly for an Asian company which seeks access to US capital markets and to a low tax Irish corporate HQ opportunity, along with global distribution. I would guess that a potential partner requested the second preclinical trial in order test whether the various enhancements and design changes produced an attractive product. My guess is that a decision will be made in the next 60 days.